AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease

In a Phase 2a study, AbbVie’s ABBV-466 achieved higher endoscopic remission rates in patients with Crohn’s disease at Week 12—the primary endpoint—than either anti-IL-23 p19 or anti-α4β7 monotherapy. The article says the treatment difference further increased after Week 12, but the reported text is truncated and gives no figures.